How to Help Your Patients Save Money on Amifampridine (Firdapse): A Provider's Guide to Savings Programs

At a list price exceeding $375,000 per year, Firdapse (amifampridine) is among the most expensive specialty medications in the United States. For many of your LEMS patients, this price tag creates immediate anxiety and treatment hesitancy — before they ever learn what the drug actually costs with assistance. As a prescriber, understanding the available savings programs and enrolling patients proactively can prevent treatment gaps, reduce financial toxicity, and improve adherence. This guide covers everything you need to know.

Why Out-of-Pocket Costs Matter for Adherence

LEMS is a progressive condition when untreated. Patients who face high out-of-pocket costs or confusion about financial assistance may delay filling prescriptions, ration doses, or abandon treatment entirely. Research across specialty medications consistently shows that high copays reduce adherence. For a LEMS patient, a treatment gap caused by cost confusion can lead to significant functional decline.

The solution is proactive enrollment in assistance programs at the time of prescribing — before the patient receives any cost information from the pharmacy.

Program 1: Catalyst Pathways — Your First Action Item

Catalyst Pathways is the comprehensive patient support program offered by Catalyst Pharmaceuticals, the maker of Firdapse. This should be the first program you initiate for every LEMS patient — ideally at the same appointment when you write the prescription.

Contact: 1-833-422-8259 | firdapse.com/support-and-savings/

What Catalyst Pathways provides for your patients:

Commercial insurance copay assistance: Eligible commercially insured patients may pay $0 per monthly prescription. Program enrollees average less than $2/month out of pocket.

Bridge program: Free medication provided to eligible patients during the insurance investigation-to-confirmation gap. Initiate this immediately if you want your patient to have medication while PA is pending.

Case manager support: Dedicated case managers help patients and offices navigate PA submissions, insurance appeals, and specialty pharmacy coordination.

Patient Assistance Program: For uninsured or underinsured patients who meet income criteria, need-based assistance may be available.

What Your Office Needs to Do for Catalyst Pathways Enrollment

Your office's role in enrollment is straightforward. To complete enrollment:

Download the enrollment form from firdapse.com/support-and-savings/ or call 1-833-422-8259 to request it

Complete the prescriber section — your signature and NPI number are required

Have the patient complete the patient section (insurance information, consent)

Submit the completed form by fax or mail as directed

A Catalyst Pathways case manager will contact you to confirm next steps and specialty pharmacy routing

Program 2: Medicare Part D — The $2,000 Annual Cap

For your Medicare patients, the 2025 Part D redesign introduced a $2,000 annual out-of-pocket cap on covered drug costs. Once a Medicare Part D beneficiary spends $2,000 in covered drug costs in a calendar year, they pay $0 for covered medications for the rest of the year. For Firdapse patients, this cap is highly significant.

Key point for Medicare patients:

Manufacturer copay cards are prohibited for Medicare beneficiaries (federal law)

The Medicare Prescription Payment Plan (M3P) allows patients to spread out-of-pocket costs over the year in monthly payments rather than paying upfront — useful for patients who struggle to pay early in the year before reaching the cap

Need-based patient assistance programs may still be available for Medicare patients who cannot afford their cost-sharing — refer to Catalyst Pathways or NORD RareCare

39,483+ patients found their medications in stock

39K+

Find Amifampridine In Stock Today →

Program 3: NORD RareCare Program

The National Organization for Rare Diseases (NORD) operates the RareCare program, which has distributed over $174 million in financial assistance to rare disease patients. For your LEMS patients who face additional financial hardship — whether commercially insured, on Medicare, or uninsured — NORD can help with:

Medication cost assistance

Insurance premium assistance

Diagnostic testing cost support

NORD RareCare contact: 1-800-999-6673 | rarediseases.org

Handling Insurance Denials That Create Cost Barriers

When coverage is denied and costs fall entirely to the patient, the financial burden becomes acute. Your response at this stage significantly impacts whether your patient can stay on therapy:

Request a peer-to-peer review: Call the insurer's medical director directly. Peer-to-peer reviews are highly effective for Firdapse denials when documentation is complete.

File a formal appeal: Submit a written medical necessity appeal with complete diagnostic documentation, functional assessments, and clinical guideline citations.

Activate the bridge program: Contact Catalyst Pathways to provide free medication while the appeal is in process.

Request external review: If internal appeals fail, patients have the right to request independent external review through their state insurance commissioner.

Skip the calls, skip the stress.

Find Amifampridine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Annual Reauthorization: Documenting Clinical Response for Continued Coverage

PA approvals for amifampridine require annual renewal. Payers require documentation of positive clinical response — improvement in dynamometry, Timed 25-Foot Walk Test, or QMG scores. Build clinical response documentation into your standard LEMS follow-up visits (every 3–6 months) so that reauthorization evidence is readily available. Track baseline functional measures at treatment initiation and record changes at each visit.

For more on helping your patients access this medication, visit medfinder for providers or read Amifampridine Shortage: What Providers and Prescribers Need to Know in 2026.